Ipratropium Bromide Nasal Spray Dosing
For adults and children aged 6 years and older with rhinorrhea from allergic or nonallergic rhinitis, use ipratropium bromide 0.03% nasal spray: 2 sprays (42 mcg) per nostril 2-3 times daily. 1
Dosing by Indication and Age
For Allergic or Nonallergic Rhinitis (0.03% concentration)
- Ages ≥6 years: 2 sprays (42 mcg) per nostril 2-3 times daily
- Approved specifically for rhinorrhea control in perennial allergic and nonallergic rhinitis 1
For Common Cold (0.06% concentration)
According to FDA labeling 2:
- Ages 12+ years: 2 sprays (84 mcg) per nostril 3-4 times daily (total 504-672 mcg/day) for up to 4 days
- Ages 5-11 years: 2 sprays (84 mcg) per nostril 3 times daily (total 504 mcg/day) for up to 4 days
- Ages 2-5 years: 2 sprays (84 mcg) per nostril 3 times daily for up to 4 days 3
For Seasonal Allergic Rhinitis (0.06% concentration)
- Ages ≥5 years: 2 sprays (84 mcg) per nostril 4 times daily (total 672 mcg/day) for up to 3 weeks 2
Key Clinical Considerations
Ipratropium bromide is indicated ONLY for rhinorrhea—it does not treat nasal congestion, sneezing, or other nasal symptoms. 1 This is a critical point: if rhinorrhea is not the primary complaint, this medication will provide minimal benefit.
Combination Therapy
When rhinorrhea persists despite other treatments, combining ipratropium 0.03% with an intranasal corticosteroid is more effective than either agent alone, without increasing adverse events. 1 This combination should be considered when:
- Rhinorrhea is one of multiple predominant symptoms
- Rhinorrhea is not fully responsive to intranasal steroids alone 4
The combination with antihistamines also provides increased efficacy over either drug alone 1.
Administration Technique
- Initial pump priming requires 7 sprays
- If unused for >24 hours: reprime with 2 sprays
- If unused for >7 days: reprime with 7 sprays
- Avoid spraying into eyes 2
Onset and Duration
- Onset of action: within 15 minutes 5
- The 0.03% concentration (42 mcg/nostril) provides effective inhibition for approximately 3 hours
- Higher doses (168 mcg/nostril) extend duration to 6 hours 5
- Fastest symptom relief occurs in the first 3 days when watery secretion predominates 6
Safety Profile
Common adverse effects include 1:
- Epistaxis (9% vs 5% with placebo)
- Nasal dryness (5% vs 1% with placebo)
- Blood-tinged mucus
These effects are generally mild, transient, and well-tolerated. The medication does not alter physiologic nasal functions (smell, ciliary beat frequency, mucociliary clearance) 1.
Systemic anticholinergic effects are minimal because ipratropium is a quaternary ammonium compound that is poorly absorbed across nasal mucosa 1.
Special Populations
Pediatric Use
- Safety and effectiveness established down to age 5 years for common cold and seasonal allergic rhinitis 2
- Safety demonstrated in ages 2-5 years, though formal effectiveness studies are limited 3
- Not established for children <5 years with allergic/nonallergic rhinitis 2
Pregnancy and Nursing
- Use caution in nursing mothers as quaternary cations may pass into breast milk 2
Clinical Context
Ipratropium bromide should be considered as first-line therapy when rhinorrhea is the predominant or sole symptom. For patients with multiple nasal symptoms, it works best as adjunctive therapy to intranasal corticosteroids rather than monotherapy. The 2008 AAAAI/ACAAI guidelines 1 provide Grade A evidence supporting its use specifically for rhinorrhea control, with the caveat that it provides no benefit for congestion, sneezing, or other symptoms.